Significantly lower risk is seen for mortality, progression, and viral clearance. 20 studies from 17 independent teams in 2 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 29% [18‑39%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies.
Results are very robust — in exclusion sensitivity analysis 14 of 27 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
4 other meta analyses show significant improvements with azvudine for mortality1-4, mechanical ventilation1, clinical improvement1, and viral clearance1,3,4.
4 meta analyses show significant improvements with azvudine for mortality
1-4,
mechanical ventilation
1,
improvement
1, and
viral clearance
1,3,4.
Covid Analysis et al., Dec 2024, preprint, 1 author.
